Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, 71041Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Sarcoma Biology Laboratory, Department of Orthopaedics, Sylvester Comprehensive Cancer Center, and the University of Miami Miller School of Medicine, Miami, FL 33136.
Cancer Control. 2021 Jan-Dec;28:10732748211045274. doi: 10.1177/10732748211045274.
The dedifferentiated variant of chondrosarcoma is highly aggressive and carries an especially grim prognosis. While chemotherapeutics has failed to benefit patients with dedifferentiated chondrosarcoma significantly, preclinical chemosensitivity studies have been limited by a scarcity of available cell lines. There is, therefore, an urgent need to expand the pool of available cell lines.
We report the establishment of a novel dedifferentiated chondrosarcoma cell line DDCS2, which we isolated from the primary tumor specimen of a 60-year-old male patient. We characterized its short tandem repeat (STR) DNA profile, growth potential, antigenic markers, chemosensitivity, and oncogenic spheroid and colony-forming capacity.
DDCS2 showed a spindle to polygonal shape and an approximate 60-hour doubling time. STR DNA profiling revealed a unique genomic identity not matching any existing cancer cell lines within the ATCC, JCRB, or DSMZ databases. There was no detectable contamination with another cell type. Western blot and immunofluorescence assays were consistent with a mesenchymal origin, and our MTT assay revealed relative resistance to conventional chemotherapeutics, which is typical of a dedifferentiated chondrosarcoma. Under three-dimensional (3D) culture conditions, the DDCS2 cells produced spheroid patterns similar to the well-established CS-1 and SW1353 chondrosarcoma cell lines.
Our findings confirm DDCS2 is a novel model for dedifferentiated chondrosarcoma and therefore adds to the limited pool of current cell lines urgently needed to investigate the chemoresistance within this deadly cancer.
去分化软骨肉瘤的变异型侵袭性强，预后极差。虽然化疗未能显著改善去分化软骨肉瘤患者的预后，但临床前化疗敏感性研究受到可用细胞系稀缺的限制。因此，迫切需要扩大可用细胞系的范围。
我们报告了一种新型去分化软骨肉瘤细胞系 DDCS2 的建立，该细胞系是从一名 60 岁男性患者的原发性肿瘤标本中分离出来的。我们对其短串联重复（STR）DNA 图谱、生长潜能、抗原标志物、化疗敏感性以及致瘤性球体和集落形成能力进行了表征。
DDCS2 呈纺锤形至多边形，倍增时间约为 60 小时。STR DNA 图谱分析显示，其基因组特征独特，与 ATCC、JCRB 或 DSMZ 数据库中现有的任何癌症细胞系均不匹配。没有检测到与其他细胞类型的污染。Western blot 和免疫荧光分析一致表明其来源于间充质，我们的 MTT 分析显示其对常规化疗药物相对耐药，这是去分化软骨肉瘤的典型特征。在三维（3D）培养条件下，DDCS2 细胞产生的球体模式类似于已建立的 CS-1 和 SW1353 软骨肉瘤细胞系。
我们的研究结果证实 DDCS2 是去分化软骨肉瘤的一种新型模型，因此增加了目前急需的细胞系范围，以研究这种致命癌症的化疗耐药性。
